呲仑帕奈的作用与功效

Perampanel is the world's first non-competitive α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor antagonist developed by Eisai INC. It was approved by the European EMA and the US FDA in July and October 2012, respectively, for the adjuvant treatment of partial-onset epilepsy in patients over 12 years old with or without secondary generalized seizures. On June 22, 2015, Eisai announced that the U.S. FDA had approved the expansion of the indications of perampanel hydrate (fycompa) as an adjuvant treatment for primary generalized tonic-clonic seizures in patients with epilepsy aged 12 years and above.

The medicine is easy to take, take it once a day before going to bed, and swallow the whole tablet. The starting dose is 2 mg/day, and the dose can be gradually increased according to clinical treatment response and tolerance, with 2 mg added at a time and an interval of 2-4 weeks. The maintenance dose is usually 4 mg/day to 8 mg/day, with the highest dose being 12 mg/day.

Numerous studies have shown that combination therapy with chirampanel is effective in the treatment of generalized seizures secondary to focal epilepsy. In the epilepsy treatment guidelines released by the United States in 2018, it is recommended as a Class A addition to the treatment of refractory focal epilepsy in adults. For adolescent patients with focal epilepsy (12-17 years old) who have received 1-3 anti-epileptic drugs but with poor results, the addition of chilampanel can significantly improve the effectiveness of treatment without significant impact on the adolescent's cognitive function, mental behavior, and growth and development (height and weight).

It was approved for marketing in China on September 29, 2019. Unfortunately, due to the short time it was on the market, the drug was not included in the Chinese Medical Insurance List. This means that patients can purchase the drug domestically, but they must purchase it at their own expense. Parampanel sold in China is very expensive, and the huge medical expenses have overwhelmed many patient families. However, according to Medical Companion Brigade, parampanel is more suitable for long-term use by patients and more cost-effective than other versions. Since the exchange rate has been in a state of fluctuation for a long time, the price fluctuates with the exchange rate and is not static. For more information about Parapanel, please contact Medical Companion Travel for details.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related articles: